BioRestorative Therapies (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem(R) program. “Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the company’s CEO. “We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem developed by BioRestorative’s scientists, enhances our ability to do so in European jurisdictions.”
To view the full press release, visit https://ibn.fm/zol25
About BioRestorative Therapies Inc.
BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company’s two core programs, brtxDISC(TM) and ThermoStem(R), relate to the treatment of disc/spine disease and metabolic disorders. For more information about the company, visit www.BioRestorative.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.